Phase I/II data on ODM-201 in mCRPC; and a Phase III trial in nmCRPC

ODM-201 is a new androgen receptor  inhibitor, initially developed by a Finnish company called Orion and now being developed by Orion in partnership with the German pharmaceutical company, Bayer. … READ MORE …

Uptake of robot-assisted radical prostatectomy in the Netherlands

There is an interesting article just published in Social Science & Medicine that addresses the social, “emotive”, and other drivers for uptake of da Vinci robot-assisted radical prostatectomy over the past few years in the Netherlands. … READ MORE …

FDA has questions about Ablatherm HIFU device

According to a report on the Bloomberg News web site, the FDA’s reviewers appear to be less than enthusiastic about the effectiveness and safety data submitted by EDAP TMS to support approval of the Ablatherm device for use of high-intensity focused ultrasound (HIFU) for the treatment of low-risk forms of prostate cancer. … READ MORE …

Quality of life after standard therapies for localized prostate cancer

Assessment of patient quality of life (QoL) after standard forms of treatment for localized prostate cancer is difficult for many reasons — not least because there is no real agreement among members of the research community about the best ways to measure QoL or patient satisfaction after treatment. … READ MORE …

IGF1 and risk for prostate cancer among African Americans

There have been suggestions that genetic variations in subtypes of insulin-like growth factor 1 (IGF1) might be responsible for at least some of the increase in risk for prostate cancer among African Americans and others of historic African ethnicity such as Afro-Caribbeans. … READ MORE …

Is baseline free serum T a factor in appropriate management on active surveillance?

Analysis of data from a cohort of 154 Chilean men with prostate cancer, all being monitored on active surveillance, suggests that free serum testosterone levels (but not total testosterone levels) may be able to help to predict which of these men will go on to need active treatment. … READ MORE …

ART or SRT in high-risk patients post-surgery?

As many of our regular readers will know, there is no clear answer to the question whether, among men at elevated risk of progressive disease after first-line surgery, it is better to have adjuvant radiation therapy (ART) within a few months of surgery or to wait until salvage radiation therapy (SRT) is clearly advisable. … READ MORE …

No 15-year survival benefit associated with primary ADT in older men

In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …

Physicians’ attitudes and the management of low-risk prostate cancer in older American men

According to newly published data in JAMA Internal Medicine and discussed on the Reuters web site today, “physician characteristics may play a larger role than disease characteristics when it comes to how patients with low-risk prostate cancer are initially treated.” This won’t come as a big surprise to most experienced prostate cancer advocates. … READ MORE …

Sociodemographics and 10-year prostate cancer survival data

The issue of sociodemographic inequality in the delivery of cancer care is well understood in America — and we don’t really know how to provide a high quality of care to those who are disadvantaged by economic factors, racial factors, or other demographic factors (such a rural vs. urban issues of access to care). … READ MORE …

The Radical Remission Project

So it is well known that some cancer patients — even (very occasionally) those with metastatic forms of prostate cancer — have what have commonly and historically been known as “spontaneous” remissions. Their apparently lethal cancers simply seem to “disappear”. Why? We really have very little idea! … READ MORE …

If you’re already depressed, you may need help to make good decisions

In a rather less that surprising finding, a new paper in the Journal of Clinical Oncology reports that men with existing depressive disorders at the time of diagnosis with prostate cancer “are less likely to undergo definitive treatment and experience worse overall survival.” … READ MORE …

Vasectomy and prostate cancer — the debate evolves

As regular readers will be well aware, the question of whether there is a real cause and effect association between having a vasectomy and the later risk for diagnosis of prostate cancer is controversial and unanswered in any absolute sense. However, there are new data that we can now put on the table … … READ MORE …

Antioxidants and cancer: do they, could they really work?

For much of the past 30 years or so there has been a great deal of effort to try to prove that antioxidants — and most specifically dietary antioxidants like some vitamins — can be used to either prevent the onset of certain cancers or to prevent the progression of early-stage cancers after a diagnosis. … READ MORE …

Will CART-type treatments be usable to treat prostate cancer?

Many of our readers may be aware of what is known as “chimeric antigen receptor T-cell” therapy (often known as CART), and its development by Carl June and colleagues at the University of Pennsylvania over the past few years. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,120 other followers